The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

exagen.com

Founded Year

2002

Stage

IPO | IPO

Total Raised

$156.13M

Date of IPO

9/19/2019

Market Cap

0.08B

Stock Price

4.78

About Exagen

Exagen is a Patient Focused, Discovery Driven, CLIA-certified, CAP-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of Rheumatology and Autoimmune diseases. Committed to Personalized Medicine, the company's Avise tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management.

Exagen Headquarter Location

1261 Liberty Way Suite C

Vista, California, 92081,

United States

+1 760 560 1501

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Exagen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Exagen is included in 4 Expert Collections, including Medical Devices.

M

Medical Devices

8,082 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health Monitoring & Diagnostics

2,394 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

B

Biopharma Tech

838 items

H

Health IT

7,900 items

Exagen Patents

Exagen has filed 17 patents.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Coagulopathies
  • Glucocorticoids
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/10/2012

11/20/2018

Autoimmune diseases, Immune system, Immunology, Inflammations, Rheumatology

Grant

Application Date

2/10/2012

Grant Date

11/20/2018

Title

Related Topics

Autoimmune diseases, Immune system, Immunology, Inflammations, Rheumatology

Status

Grant

Latest Exagen News

Bitcoin Now Buys You the Greatest Amount of Exagen in the Past Year

May 19, 2022

Bitcoin Now Buys You the Greatest Amount of Exagen in the Past Year Middle East Bitcoin Now Buys You the Greatest Amount of Exagen in the Past Year Here at CryptocurrenciesChannel.com, we find it interesting to track various ETF and stock prices versus various digital assets over time.

Exagen Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Exagen Rank

  • When was Exagen founded?

    Exagen was founded in 2002.

  • Where is Exagen's headquarters?

    Exagen's headquarters is located at 1261 Liberty Way, Vista.

  • What is Exagen's latest funding round?

    Exagen's latest funding round is IPO.

  • How much did Exagen raise?

    Exagen raised a total of $156.13M.

  • Who are Exagen's competitors?

    Competitors of Exagen include CivaTech Oncology, Decipher Biosciences, Biodesix, Progentec Diagnostics, Integrated Diagnostics, Foundation Medicine, Daktari Diagnostics, Signature Diagnostics, On-Q-ity, SourceMDx and 12 more.

You May Also Like

C
Cellpoint Diagnostics

CellPoint Diagnostics is developing diagnostic, monitoring, and molecular analytical tools for cancer. Its technology captures and analyzes circulating tumor cells ("CTCs") directly from patient blood. Scientific and clinical data have demonstrated that CTCs are derived from the primary tumor, and the assessment of the number of CTCs in the blood has been shown to accurately predict survival for cancer patients.

N
NeoDiagnostix

NeoDiagnostix develops molecular diagnostic and prognostic tests for the treatment of cancer. The company's test results eliminate the ambiguity experienced in millions of samples analyzed by traditional cytomorphology-based cell analyses. The company is committed to providing physicians with information that will improve patient care and treatment.

N
Nanogen Adavanced Diagnostics S.r.l.

At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.

P
Prognomix

Predict to Prevent  Prognomixs vision is the development of personalized medicine for the early detection of susceptibilities to diseases their complications and individual therapeutic responsiveness using genomic signatures Their initial focus is the development  of  presymptomatic diagnostic tools of diabetic complications based on genomic signatures aimed at individualized targeted prevention

E
Expression Diagnostics

XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. Per the company, they have developed a proprietary method of utilizing gene expression in blood that aims to provide a new tool for physicians to manage the care of heart transplant patients. The molecular expression technology developed and implemented by XDx in heart transplant patient management is currently being explored to assist with other diseases that involve the immune system.

CivaTech Oncology Logo
CivaTech Oncology

Civatech Oncology is a medical device company focused on the development of polymer based devices that treat cancer using localized, low-dose-rate radiation. The company's fabrication methods allow for precise encapsulation of radioactive materials into polymer structures. These polymer-based brachytherapy devices offer physicians treatment options for tumors with low-dose-rate brachytherapy.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.